Premium
Retrograde intra‐arterial chemotherapy and daily concurrent proton beam therapy for recurrent oral cavity squamous cell carcinoma: Analysis of therapeutic results in 46 cases
Author(s) -
Hayashi Yuichiro,
Nakamura Tatsuya,
Mitsudo Kenji,
Yamaguchi Hisashi,
Ono Takashi,
Azami Yusuke,
Takayama Kanako,
Suzuki Motohisa,
Hatayama Yoshiomi,
Tsukiyama Iwao,
Hareyama Masato,
Kikuchi Yasuhiro,
Fuwa Nobukazu,
Tohnai Iwai
Publication year - 2016
Publication title -
head and neck
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.012
H-Index - 127
eISSN - 1097-0347
pISSN - 1043-3074
DOI - 10.1002/hed.24421
Subject(s) - medicine , docetaxel , chemotherapy , cisplatin , basal cell , head and neck , head and neck squamous cell carcinoma , proton therapy , head and neck cancer , oral cavity , urology , surgery , radiation therapy , dentistry
Background The purpose of this study was to evaluate the efficacy and toxicities of proton beam therapy combined with intra‐arterial infusion chemotherapy via superficial temporal and occipital arteries for recurrent oral cavity squamous cell carcinoma (SCC). Methods Between October 2009 and June 2013, 46 patients with recurrent oral cavity SCC were treated by proton beam therapy combined with intra‐arterial infusion chemotherapy of cisplatin (CDDP) and docetaxel. Treatment consisted of proton beam therapy (28.6–74.8 GyE in 13–34 fractions) and intra‐arterial infusion chemotherapy (CDDP, 30–50 mg/body/week; docetaxel, 5–25 mg/body/week). Results One‐year and 2‐year overall survival (OS) rates were 65% and 46%, respectively. One‐year and 2‐year local control rates were 81% and 70%, respectively. Conclusion These findings suggest that proton beam therapy combined with intra‐arterial infusion chemotherapy could be applied effectively and safely for patients with recurrent oral cavity SCC. © 2016 Wiley Periodicals, Inc. Head Neck 38:1145–1151, 2016